Researchers from Washington University in St. Louis reported data validating microtubule-binding region (MTBR) of tau containing the residue 243 (MTBR-tau243) as a new cerebrospinal fluid (CSF) biomarker specific for insoluble tau aggregates in Alzheimer’s disease (AD).
